Belimumab was recently shown to reduce disease activity in patients with systemic lupus erythematosus. This observation raises important questions about where belimumab might best fit into the ...
B cells have important pathogenic roles in systemic lupus erythematosus (SLE): they ... now report favorable results for their phase I trial of belimumab—a fully human, neutralizing, monoclonal ...
Lupus activity was defined by presence of SS ... There were initially three belimumab groups (1, 4 or 10 mg/kg every 4 weeks) and a placebo group enrolled in a 52-week trial.
Uptake of belimumab continues to outpace the use of anifrolumab among clinicians managing patients with systemic lupus erythematosus, according to a survey conducted by Spherix Global Insights.
However, for the vast majority of lupus flares the initial treatment ... disease in the long term and avoid 'spare' glucocorticoids Belimumab Minor arthritis, mild pleurisy NSAIDs Addition of ...
In a new study published in Lupus Science & Medicine, researchers explored the efficacy of using a combination of belimumab and standard immunotherapy compared to standard immunotherapy alone in ...
The US FDA has approved GSK’s Benlysta (belimumab) intravenous infusion for the treatment of children with lupus. While childhood-onset lupus is rare, when diagnosed, it is generally more active ...
GlaxoSmithKline’s Benlysta has been on the market for almost a decade, but it still has some tricks up its sleeve – it’s just become the first and only FDA-approved treatment for lupus ...
Uptake of belimumab continues to outpace the use of anifrolumab among clinicians managing patients with systemic lupus erythematosus, according to a survey conducted by Spherix Global Insights.
Lupus is typically treated with anti-inflammatory ... In severe cases, rituximab and belimumab might be administered to target the number of antibodies in the blood and boost the immune system.
But this past year, decades of hard work led to three new drugs receiving FDA-approval for the treatment of lupus and lupus nephritis: Belimumab (Benlysta), Voclosporin (Lupkynis), and Aanifrolumab ...